# Ron Johnson

Type: Person

Source: Legal & RegTech Intelligence Brief — https://getlegalbrief.com/entity/ron-johnson
Canonical HTML page: https://getlegalbrief.com/entity/ron-johnson

## Timeline

- **2026-06-19**: Senators react — Sens. Rand Paul and Ron Johnson publicly call for legal challenges to the pardon, state-level prosecution, and full investigations into Fauci’s actions.
- **2026-06-18**: Gabbard releases intelligence files — Outgoing DNI Tulsi Gabbard declassifies and releases trove of documents alleging Fauci’s deception and funding of Wuhan gain-of-function research.
- **2026-03-11**: Document Request — Expected date for formal requests for internal FDA communications regarding DMD drug applications.
- **2026-03-10**: Investigation Announced — Sen. Ron Johnson publicly declares a formal inquiry into the FDA's rare disease drug approval process.
- **2026-03-10**: Commissioner Consultation — Johnson speaks with FDA Commissioner Marty Makary to discuss specific drug rejections and agency policy.
- **2025-01**: Preemptive pardon granted — President Biden issues a preemptive pardon to Fauci before leaving office, covering potential federal crimes related to the pandemic.
- **2024**: Fauci testifies to Congress — Fauci testifies that he had no contact with intelligence agencies regarding viral research, a claim now contradicted by Gabbard's files.

## Recent coverage (2 stories)

### Fauci’s 2025 Pardon in Jeopardy: Gabbard Dump Reveals Alleged Lies & Obstruction
2026-07-31 16:50:17 · Sentiment: Very Bearish · Impact: 6/10 · Sources: 2

Outgoing DNI Tulsi Gabbard’s declassification of intelligence files intensifies legal scrutiny on Anthony Fauci, revealing potential perjury and evidence destruction that could pierce his 2025 preemptive pardon and open the door to state-level prosecutions.
Full story: https://getlegalbrief.com/story/gabbard-fauci-pardon-legal-challenge

### Senator Johnson Launches Investigation into FDA Rare Disease Drug Denials
2026-03-10 22:17:42 · Sentiment: Neutral · Impact: 6/10 · Sources: 2

Senator Ron Johnson (R-Wis.) has initiated a formal investigation into the FDA’s regulatory processes regarding the rejection of biologic therapies for Duchenne muscular dystrophy and other rare diseases. The probe follows high-level discussions with FDA Commissioner Marty Makary and focuses on whether the agency's evidentiary standards are too restrictive for life-threatening conditions.
Full story: https://getlegalbrief.com/story/senator-johnson-fda-rare-disease-investigation

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getlegalbrief.com/guides/methodology for the full editorial methodology.